Between the Hammer and Anvil: Resolution of unresectable muscle invasive bladder cancer in a renal transplant patient after cessation of immunosuppressive therapy

• DOI: 10.1016/j.eucr.2023.102399
• Publication Date: 2023-04-17T09:56:21Z
• Authors: David Strauss; Briana Kaplunov; Alexander Kutikov; Daniel M. Geynisman; Kwan Lau; Marc Smaldone
• Keywords: Immunosuppression; Concomitant; Regimen

Multimodal immunosuppression is the backbone of modern solid organ transplantation. However, itself an independent risk factor for post-transplant malignancy. Although skin malignancy most common malignancy, genitourinary cancers are also described. Dose reduction or cessation has a beneficial role in management transplant patients with concomitant but only limited data exist respect to bladder cancer (BCa). We describe patient who developed metastatic muscle invasive (MIBC) after diseased donor kidney (DDKT) was successfully managed dose and elimination regimen.